Total trials
4,664
Capped at 5,000
Active
1,281
Phase 3
217
Total enrollment
15,516,963
Pipeline matrix
Showing 40 of 237 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexmedetomidine | — | 70 | |||||
| Bupivacaine | — | — | 40 | ||||
| Fentanyl | — | — | 18 | ||||
| Ketamine | — | 22 | |||||
| Nalbuphine | — | — | 10 | ||||
| Dexamethasone | — | 32 | |||||
| Normal saline | — | 24 | |||||
| MgSO4 | — | — | — | 4 | |||
| Dextrose 5% | — | — | — | — | — | 2 | |
| Propofol | — | — | 11 | ||||
| Bupivacaine 0.5% | — | — | — | 4 | |||
| Methylprednisolone | — | — | — | 4 | |||
| Magnesium Sulfate and Bupivacaine 0.125% | — | — | — | — | 3 | ||
| Azithromycin | — | — | — | — | 3 | ||
| Granisetron | — | — | — | 5 | |||
| Triamcinolone Acetonide | — | — | — | — | 4 | ||
| Hyaluronic Acid | — | — | — | — | 2 | ||
| Dexamethasone and Ondansetron | — | — | — | — | — | 1 | |
| Bupivacaine + saline | — | — | — | — | — | 1 | |
| Vitamin E | — | — | — | — | — | 1 | |
| Sodium Valproate 500 Mg Prolonged-Release Oral | — | — | — | — | — | 1 | |
| Lamotrigine | — | — | — | — | — | 1 | |
| Levobupivacaine + Dexmedetomidine | — | — | — | — | — | 1 | |
| Lidocaine %2 ampoule | — | — | — | — | — | 1 | |
| Topical nano preparation of Phenytoin | — | — | — | — | — | 1 | |
| Nebulization of dexmedetomidine and ketamine | — | — | — | — | — | 1 | |
| Nebulization of dexmedetomidine | — | — | — | — | — | 1 | |
| Topical Vancomycin Powder | — | — | — | — | — | 1 | |
| Bupivacaine with Dexamethasone Solution | — | — | — | — | — | 1 | |
| clonidine 1 mg / kg | — | — | — | — | — | 1 | |
| Magnesium Sulphate 500 mg | — | — | — | — | — | 1 | |
| dexmedetomidine + propofol | — | — | — | — | — | 1 | |
| Propofol alone | — | — | — | — | — | 1 | |
| Botulinum Toxin-A | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Lidocaine 2 % | — | — | — | — | — | 1 | |
| vasline | — | — | — | — | — | 1 | |
| B-sitosterol | — | — | — | — | — | 1 | |
| Morphine - .25 mg | — | — | — | — | — | 1 | |
| fentanyl + morphine | — | — | — | — | — | 1 |
197 more active programs hidden
Next readouts
- 2024-07-20
- 2024-07-30
- 2024-08-01
- 2024-08-13
- 2024-09-01
- 2024-10-01
- 2024-12
- 2024-12
- 2024-12-01
- 2024-12-20
Top conditions
- Postoperative Pain58
- Breast Cancer47
- Rheumatoid Arthritis32
- Inflammatory Bowel Diseases29
- Covid1928
- COVID-1925
- Acute Kidney Injury21
- Systemic Lupus Erythematosus18
Frequently asked questions about Assiut University
- How many clinical trials does Assiut University have on ClinicalTrials.gov?
- Assiut University is listed as the lead sponsor on 4,664 clinical trials in ClinicalTrials.gov, 1,281 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Assiut University's trials are in Phase 3?
- 217 of Assiut University's trials are in Phase 3, spread across 237 active drug programs.
- What therapeutic areas does Assiut University focus on?
- Assiut University's most-studied conditions on ClinicalTrials.gov are Postoperative Pain, Breast Cancer, Rheumatoid Arthritis, Inflammatory Bowel Diseases, Covid19.
- When are Assiut University's next clinical trial readouts?
- Assiut University has 10 upcoming primary-completion readouts tracked here; the soonest is “Different Methods of Tranexamic Acid Application in Controlling Peri Operative Bleeding in Gynecomastia Surgery”, expected around 2024-07-20.